IOVANCE BIOTHERAPEUTICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $11.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $11.20M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $16.90M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $5.80M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $11.70M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $11.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $16.90M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $5.80M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $11.70M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $16.60M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $5.70M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.80M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $15.80M 10-Q · filed 2024-05-09 |
| 2023-09-30 | $3.90M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $7.90M 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |